lamivudine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adinolfi, LE; Boemio, A; Capoluongo, N; Coppola, N; D'Amore, C; Esposito, M; Guastafierro, S; Macera, M; Marrone, A; Mastrullo, L; Minichini, C; Onorato, L; Pisaturo, M; Rinaldi, L; Sagnelli, E; Siniscalchi, I | 1 |
| Chtioui, H; Lämmle, B; Lauterburg, BH; Millius, C | 1 |
| Aki, Z; Haznedar, R; Ozkurt, ZN; Sucak, GT; Yağci, M; Yeğin, ZA | 1 |
| Dietzel, T; Eucker, J; Fleissner, C; Heider, U; Jakob, C; Ockenga, J; Possinger, K; Sezer, O; Zavrski, I | 1 |
| Abbadessa, V; Ammatuna, E; Calvaruso, G; Craxí, A; Di Stefano, R; Di Trapani, R; Ferraro, D; Iannitto, E; Minardi, V; Mulè, A; Stefano, RD; Trapani, RD | 1 |
| Colombo, M; Cortelezzi, A; Deliliers, GL; Fantini, NN; Lampertico, P; Pasquini, MC; Viganò, M; Zilioli, VR | 1 |
| Acar, K; Aki, Z; Bozdayi, G; Haznedar, R; Sucak, GT; Yağci, M | 1 |
| Motta, M; Pelizzari, A; Puoti, M; Rossi, G | 1 |
2 trial(s) available for lamivudine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Rituximab; Virus Activation | 2010 |
A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues.
Topics: 2-Aminopurine; Adult; Aged; Antineoplastic Agents; Antiviral Agents; Chronic Disease; Famciclovir; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleosides; Pilot Projects; Prospective Studies; Virus Activation | 2006 |
6 other study(ies) available for lamivudine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Virus Activation; Young Adult | 2018 |
Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation.
Topics: Antineoplastic Agents; Cladribine; Drug Interactions; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Treatment Failure | 2009 |
Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Time Factors; Treatment Outcome | 2004 |
Hepatitis B virus reactivation and alemtuzumab therapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppression Therapy; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Reverse Transcriptase Inhibitors; Virus Activation | 2005 |
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Organophosphonates; Recurrence; Treatment Outcome | 2006 |
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hodgkin Disease; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Vidarabine; Vincristine; Virus Activation | 2001 |